electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
8.72
-1.22 (-12.27%)
At close: Jun 5, 2026, 4:00 PM EDT
8.71
-0.01 (-0.11%)
After-hours: Jun 5, 2026, 5:28 PM EDT
electroCore Revenue
electroCore had revenue of $9.58M in the quarter ending March 31, 2026, with 42.64% growth. This brings the company's revenue in the last twelve months to $34.90M, up 31.90% year-over-year. In the year 2025, electroCore had annual revenue of $32.03M with 27.20% growth.
Revenue (ttm)
$34.90M
Revenue Growth
+31.90%
P/S Ratio
2.07
Revenue / Employee
$420,446
Employees
83
Market Cap
72.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.03M | 6.85M | 27.20% |
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | 2.39M | 1.40M | 140.72% |
| Dec 31, 2018 | 992.95K | 181.50K | 22.37% |
| Dec 31, 2017 | 811.46K | 557.32K | 219.30% |
| Dec 31, 2016 | 254.14K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuronetics | 151.64M |
| Xtant Medical Holdings | 121.91M |
| Outset Medical | 117.59M |
| Pulmonx | 88.55M |
| LENSAR | 57.70M |
| Rapid Micro Biosystems | 34.38M |
| MaxCyte | 32.29M |
| QT Imaging Holdings | 22.66M |
ECOR News
- 5 days ago - electroCore management to meet with Maxim - TheFly
- 5 days ago - electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub - GlobeNewsWire
- 20 days ago - electroCore Transcript: 16th Annual LD Micro Invitational Conference - Transcripts
- 25 days ago - electroCore Quell study shows fibromyalgia pain reduction - TheFly
- 25 days ago - electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia - GlobeNewsWire
- 4 weeks ago - electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 - GlobeNewsWire
- 4 weeks ago - electroCore price target lowered to $19.85 from $22 at Ladenburg - TheFly
- 4 weeks ago - electroCore reports Q1 EPS (59c) vs. (47c) last year - TheFly